Authors
Himisha Beltran, Kenneth Eng, Juan Miguel Mosquera, Alexandros Sigaras, Alessandro Romanel, Hanna Rennert, Myriam Kossai, Chantal Pauli, Bishoy Faltas, Jacqueline Fontugne, Kyung Park, Jason Banfelder, Davide Prandi, Neel Madhukar, Tuo Zhang, Jessica Padilla, Noah Greco, Terra J McNary, Erick Herrscher, David Wilkes, Theresa Y MacDonald, Hui Xue, Vladimir Vacic, Anne-Katrin Emde, Dayna Oschwald, Adrian Y Tan, Zhengming Chen, Colin Collins, Martin E Gleave, Yuzhuo Wang, Dimple Chakravarty, Marc Schiffman, Robert Kim, Fabien Campagne, Brian D Robinson, David M Nanus, Scott T Tagawa, Jenny Z Xiang, Agata Smogorzewska, Francesca Demichelis, David S Rickman, Andrea Sboner, Olivier Elemento, Mark A Rubin
Publication date
2015/7/1
Journal
JAMA oncology
Volume
1
Issue
4
Pages
466-474
Publisher
American Medical Association
Description
Importance
Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer.
Objective
To understand how WES data affect therapeutic decision making in patients with advanced cancer and to identify novel biomarkers of response.
Design, Setting, and Patients
Patients with metastatic and treatment-resistant cancer were prospectively enrolled at a single academic center for paired metastatic tumor and normal tissue WES during a 19-month period (February 2013 through September 2014). A comprehensive computational pipeline was used to detect point mutations, indels, and copy number alterations. Mutations were categorized as category 1, 2, or 3 on …
Scholar articles
H Beltran, K Eng, JM Mosquera, A Sigaras, A Romanel… - JAMA oncology, 2015